12 Month Price Forecast For DVA
Distance to DVA Price Forecasts
DVA Price Momentum
๐ค Considering DaVita (DVA)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 6:42 AM UTC
DVA Analyst Ratings & Price Targets
Based on our analysis of 10 Wall Street analysts, DVA has a neutral consensus with a median price target of $164.00 (ranging from $134.00 to $186.00). The overall analyst rating is Buy (6.2/10). Currently trading at $173.52, the median forecast implies a -5.5% downside. This outlook is supported by 1 Buy, 7 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Andrew Mok at UBS, suggesting a 22.8% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DVA Analyst Consensus
DVA Price Target Range
Latest DVA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DVA.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Oct 31, 2024 | Barclays | Andrew Mok | Equal-Weight | Maintains | $164.00 |
Oct 7, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $175.00 |
Aug 20, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $165.00 |
Aug 8, 2024 | UBS | Andrew Mok | Buy | Maintains | $175.00 |
Aug 7, 2024 | B of A Securities | Kevin Fischbeck | Underperform | Maintains | $145.00 |
Jul 24, 2024 | TD Cowen | Gary Taylor | Hold | Maintains | $150.00 |
May 15, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $150.00 |
May 6, 2024 | Barclays | Andrew Mok | Equal-Weight | Maintains | $150.00 |
Mar 6, 2024 | Barclays | Sarah James | Equal-Weight | Initiates | $133.00 |
Feb 20, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $135.00 |
Feb 15, 2024 | UBS | Andrew Mok | Buy | Maintains | $145.00 |
Feb 14, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $130.00 |
Feb 14, 2024 | UBS | Andrew Mok | Buy | Maintains | $134.00 |
Nov 17, 2023 | UBS | Andrew Mok | Buy | Maintains | $113.00 |
Oct 11, 2023 | Truist Securities | David Macdonald | Hold | Maintains | $104.00 |
Aug 7, 2023 | UBS | Andrew Mok | Buy | Upgrade | $142.00 |
Jul 13, 2023 | Truist Securities | David Macdonald | Hold | Maintains | $115.00 |
May 15, 2023 | Bernstein | Lisa Bedell Clive | Market Perform | Maintains | $100.00 |
May 9, 2023 | B of A Securities | Kevin Fischbeck | Underperform | Maintains | $96.00 |
May 9, 2023 | Truist Securities | David Macdonald | Hold | Maintains | $100.00 |
Stocks Similar to DaVita Inc
The following stocks are similar to DaVita based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
DaVita Inc (DVA) Financial Data
DaVita Inc has a market capitalization of $14.15B with a P/E ratio of 18.6x. The company generates $12.67B in trailing twelve-month revenue with a 6.5% profit margin.
Revenue growth is +4.6% quarter-over-quarter, while maintaining an operating margin of +16.3% and return on equity of +44.9%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

DaVita Inc (DVA) Company Overview
About DaVita Inc
Provides kidney dialysis services to patients.
The company operates kidney dialysis centers and offers a variety of services, including outpatient and home-based hemodialysis, as well as lab services. It generates revenue through patient treatments, laboratory services, and management services for outpatient centers, alongside integrated care arrangements and clinical research programs.
Incorporated in 1994 and headquartered in Denver, Colorado, DaVita Inc. was previously known as DaVita HealthCare Partners Inc. The company has expanded its services to include acute inpatient dialysis and transplant software solutions, enhancing its comprehensive kidney care offerings.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
70,000
CEO
Mr. Javier J. Rodriguez
Country
United States
IPO Year
1995
Website
www.davita.comDaVita Inc (DVA) Latest News & Analysis
DaVita HealthCare (DVA) closed at $177.35, reflecting a 0.16% increase from the prior trading day.
DaVita HealthCare's slight price increase indicates stability and may reflect positive market sentiment, influencing investor confidence and future trading decisions.
Warren Buffett, renowned investor and leader of Berkshire Hathaway, is a key figure in investment strategy, with many investors attempting to emulate his approach.
Warren Buffett's investing strategy influences market trends and investor behavior, making Berkshire Hathaway's holdings a key indicator for potential investment opportunities.
DaVita Inc. (NYSE: DVA) will hold its fourth quarter results conference call on February 13, 2025, at 5:00 p.m. Eastern Time.
DaVita's upcoming quarterly call will provide insights into its financial performance, which can influence stock price and investor sentiment. Key metrics discussed may affect investment decisions.
Investors are focusing on bullish stocks, including ENS, DVA, REVG, and PAA, which are experiencing price strength and expected to maintain momentum.
Bullish momentum in stocks like ENS, DVA, REVG, and PAA indicates potential for further price appreciation, attracting investor interest and driving demand.
Sell Nvidia, Buy This Stock
14 days agoNo specific details were provided about the events that occurred over the weekend. Investors should seek further information for context and implications.
Vague news can indicate potential market volatility or shifts in sentiment, prompting investors to stay alert to new developments that could impact asset valuations.
DaVita HealthCare (DVA) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating positive earnings outlook and potential for short-term stock price increase.
DaVita HealthCare's upgrade to a Zacks Rank #1 signals strong earnings potential, likely boosting investor confidence and driving the stock price upward.
Frequently Asked Questions About DVA Stock
What is DaVita Inc's (DVA) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, DaVita Inc (DVA) has a median price target of $164.00. The highest price target is $186.00 and the lowest is $134.00.
Is DVA stock a good investment in 2025?
According to current analyst ratings, DVA has 1 Buy ratings, 7 Hold ratings, and 1 Sell ratings. The stock is currently trading at $173.52. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for DVA stock?
Wall Street analysts predict DVA stock could reach $164.00 in the next 12 months. This represents a -5.5% decrease from the current price of $173.52. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is DaVita Inc's business model?
The company operates kidney dialysis centers and offers a variety of services, including outpatient and home-based hemodialysis, as well as lab services. It generates revenue through patient treatments, laboratory services, and management services for outpatient centers, alongside integrated care arrangements and clinical research programs.
What is the highest forecasted price for DVA DaVita Inc?
The highest price target for DVA is $186.00 from at , which represents a 7.2% increase from the current price of $173.52.
What is the lowest forecasted price for DVA DaVita Inc?
The lowest price target for DVA is $134.00 from Andrew Mok at UBS, which represents a -22.8% decrease from the current price of $173.52.
What is the overall DVA consensus from analysts for DaVita Inc?
The overall analyst consensus for DVA is neutral. Out of 10 Wall Street analysts, 1 rate it as Buy, 7 as Hold, and 1 as Sell, with a median price target of $164.00.
How accurate are DVA stock price projections?
Stock price projections, including those for DaVita Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.